Investigation of differentially expressed gene profile for cisplatin-treated lung cancer patients. Issue 8 (6th May 2021)

• Record Type: Journal Article
• Authors: Gu, Songtao; Wu, Qi; Li, Yuechuan; Jia, Wei; Zhang, Dongrui; Jiao, Lina; Zhang, Yating
• Is Part Of: Anti-cancer drugs. Volume 32:Issue 8(2021)
• Page Start: 875
• Page End: 881
• Publication Date: 2021-05-06
• Subjects: cisplatin -- immune checkpoints -- lung cancer -- protein–protein interaction analysis; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001075
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Supplemental Digital Content is available in the text. Abstract : The purpose of the study was to establish a comprehensive differential gene profile for lung cancer patients treated with cisplatin compared with control patients without any chemotherapy drug treatment. The RNA sequencing data and miRNA sequencing data of 108 lung cancer patients treated with cisplatin only and 232 lung cancer patients treated without any chemotherapeutic drugs, were analyzed using differential expression, protein–protein interaction, and immune cell infiltration ratio analysis. Compared with control patients, the cisplatin-treated patients demonstrated 336 differentially expressed genes, which included 48 upregulated genes and 288 downregulated genes. Meanwhile, 12 differentially expressed miRNAs (DEMs), including 7 upregulated miRNAs and 5 downregulated miRNAs showed a differentially expressed pattern. With further instigation, five miRNAs (hsa-miR-548ah, hsa-miR-466, hsa-miR-552, hsa-miR-371a, and hsa-miR-4445) were suggested to be the key targets in the cisplatin-treated patients. At the same time, we also found a significant correlation between the cisplatin treatment and six immune checkpoints including programmed cell death ligand. This study helped us better understand the potential targets and underline molecular mechanisms for cisplatin treatment and provided references to eliminate existing side effects in the future.